Chemo Tied to Gut Microbiome Changes and Associated Cognitive Decline
By Lori Solomon HealthDay Reporter
TUESDAY, July 23, 2024 -- Gut microbiome change is associated with cognitive decline during chemotherapy for patients with breast cancer, according to a study published online in the August issue of Brain, Behavior, and Immunity.
Lauren D. Otto-Dobos, Ph.D., from the Institute for Behavioral Medicine Research at The Ohio State University in Columbus, and colleagues analyzed fecal samples, blood samples, and cognitive measures from 77 patients with breast cancer before, during, and after chemotherapy.
The researchers found that chemotherapy altered the gut microbiome community structure and increased circulating tumor necrosis factor-alpha (TNF-α). The chemotherapy-induced changes in microbial relative abundance and decreased microbial diversity both were associated with elevated circulating pro-inflammatory cytokines TNF-α and interleukin-6. Participant-reported subjective cognitive decline during chemotherapy was not associated with changes in the gut microbiome or inflammatory markers. However, a decrease in overall objective cognition was associated with a decrease in microbial diversity, independent of circulating cytokines. Compared to individuals without cognitive decline, those with cognitive decline (35 percent) had unique taxonomic shifts in Faecalibacterium, Bacteroides, Fusicatenibacter, Erysipelotrichaceae UCG-003, and Subdoligranulum over the course of chemotherapy treatment.
"These results suggest that microbiome-related strategies may be useful for predicting and preventing behavioral side effects of chemotherapy," the authors write.
One author disclosed ties to Scioto Biosciences.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM
THURSDAY, April 17, 2025 -- Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk...
Disparities Evident in Treatment, Survival for Patients With Pancreatic Cancer
THURSDAY, April 17, 2025 -- Among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), racial and ethnic minority patients and socially vulnerable populations are...
Air Pollution Exposure Negatively Impacts Some Domains of Cognitive Performance
TUESDAY, April 15, 2025 -- Air pollution is associated with domain-specific impacts on cognitive performance in older adults, according to a study published online March 17 in The...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.